These agents are advocated to cause RNA-processing abnormalities, disrupted nucleocytoplasmic transport and consequent protein aggregation, neuroinflammation, deficits in protein quality control mechanisms, as well as the TAR DNA-binding protein 43 (TDP-43) expression observed in motor neurons and glial cells of around 97% ALS patients [458]. This evidence concerns the gene TARDBP and amyotrophic lateral sclerosis.